PLSE:NASDAQPulse Biosciences, Inc Analysis

Pulse Biosciences is trading at $25.61, comfortably above its 20‑day SMA (22.13) and 50‑day SMA (21.48), with the 200‑day SMA (17.56) well below, confirming a strong bullish trend. The RSI of 61 and a bullish MACD histogram (+0.59) further support momentum, while the price sits near the upper end of its 52‑week range and only $2.37 below the identified resistance of $27.98, suggesting limited upside in the immediate term but still a projected 17% upside based on current metrics. Fundamentally, the company remains distressed – it reports negative gross margins (‑21%), operating losses exceeding $76 M, and zero earnings per share, resulting in a forward PE of ‑29 and a sky‑high price‑to‑book of 21.5. However, the balance sheet shows a solid cash cushion of roughly $68 M (augmented to $119 M per the latest cash update) against modest debt, and recent news highlights a growing cash position, an ATM equity raise by insiders, and progress in clinical pilots for thyroid nodules and the nPulse Cardiac Catheter, which could unlock future revenue streams. Volatility remains extreme (108% 30‑day) and beta is elevated (≈2.2), indicating the stock is highly sensitive to market swings**, but the increasing volume trend and strong analyst sentiment (strong‑buy recommendation) suggest that investors are betting on the upcoming clinical data to catalyze a turnaround.